TransMedics Q2 net income declines on R&D and infrastructure expenses

TransMedics

04/08/2026 21:44

Overview
US organ transplant tech firm's Q2 revenue rose 21%, beating analyst expectations
Adjusted EPS for Q2 was $0.44; no analyst consensus for comparison
Company raised low end of 2026 revenue guidance and invested in PAD Aviation for EU logistics

Outlook
TransMedics raises low end of 2026 revenue guidance to $737 mln-$757 mln, excluding PAD Aviation
Company's 2026 revenue outlook assumes no incremental revenue from ENHANCE Part B and DENOVO trials

Result Drivers
OCS UTILIZATION - Co said revenue growth was primarily driven by increased use of Organ Care System, especially in liver and heart transplants through National OCS Program
SERVICE REVENUE MIX - Higher proportion of service revenue and temporary product-cost factors weighed on gross margin
R&D AND INFRASTRUCTURE SPEND - Operating expenses increased due to investment in OCS Kidney, Gen 3.0, clinical programs and infrastructure

Company press release: ID:nPn1V9jp7a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$189.90 mln
$183.64 mln (11 Analysts)
Q2 EPS
 
$0.41
 
Q2 Net Income
 
$14.70 mln
 
Q2 Gross Margin
 
60.00%
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Transmedics Group Inc is $120.00, about 47.1% above its August 3 closing price of $81.55
The stock recently traded at 32 times the next 12-month earnings vs. a P/E of 35 three months ago

Reuters Recommended Reads
Aug 3 - UFP Technologies Q2 revenue beats estimates on the back of medtech segment
Aug 3 - Viemed Healthcare Q2 revenue rises on ventilator patient growth
Aug 4 - AdaptHealth Q2 revenue misses estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)